Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 8/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30276043 | 1.00 | PIK3CD (0.51) | PIK3CDKCNH2PDE4APDE4BPDE4C | |
| SCHEMBL18038546 | 1.00 | PIK3CD (0.51) | PIK3CDKCNH2PDE4APDE4BPDE4C | |
| SCHEMBL28964731 | 1.00 | PIK3CD (0.51) | PIK3CDKCNH2PDE4APDE4BPDE4C | |
| SCHEMBL30276060 | 0.89 | PIK3CD (0.49) | PIK3CDKCNH2PDE4APDE4BPDE4C | |
| SCHEMBL28952257 | 0.89 | PIK3CD (0.49) | PIK3CDKCNH2PDE4APDE4BPDE4C | |
| SCHEMBL28952254 | 0.89 | PIK3CD (0.49) | PIK3CDKCNH2PDE4APDE4BPDE4C | |
| SCHEMBL30275998 | 0.89 | PIK3CD (0.49) | PIK3CDKCNH2PDE4APDE4BPDE4C | |
| SCHEMBL28952186 | 0.88 | PIK3CD (0.51) | PIK3CDKCNH2PDE4APDE4BPDE4C | |
| SCHEMBL30276037 | 0.88 | PIK3CD (0.51) | PIK3CDKCNH2PDE4APDE4BPDE4C | |
| SCHEMBL18038551 | 0.85 | PIK3CD (0.47) | PIK3CDKCNH2PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3801533-B1 | DOSING REGIMEN FOR THE TREATMENT OF PI3K RELATED DISORDERS | INCYTE CORP (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250289823-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION | 2025-09-18 | — | — | US | disclosed |
| CN-120053645-A | Dosing regimen for treating PI 3K-related disorders | 因赛特公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20250129079-A1 | SALTS AND PROCESSES OF PREPARING A PI3K INHIBITOR | INCYTE CORPORATION | 2025-04-24 | — | — | US | disclosed |
| EP-3888657-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12226418-B2 | Dosing regimen for the treatment of PI3K related disorders | INCYTE CORPORATION (US) | 2025-02-18 | — | — | US | disclosed |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| CN-119258070-A | Dosing regimen for treating PI 3K-related disorders | 因赛特公司 | 2025-01-07 | — | — | CN | disclosed |
| US-12152033-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders | INCYTE CORPORATION (US) | 2024-11-26 | — | — | US | disclosed |
| WO-2014134426-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014134426-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20140249132-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | US | disclosed |
| CN-104024253-A | Heterocyclic amines as PI3K inhibitors | INCYTE CORP | 2014-09-03 | — | — | CN | disclosed |
| EP-2751109-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033569-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033569-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249132-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | PIK3CD 1/4885KCNH2 2105/4885PDE4A 359/4885 |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885KCNH2 3201/4885PDE4A 806/4885 |
| US-12152033-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885KCNH2 2594/4885PDE4A 444/4885 |
| US-20250289823-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | PIK3CD 1/4885KCNH2 2105/4885PDE4A 359/4885 |
| US-20250129079-A1 | SALTS AND PROCESSES OF PREPARING A PI3K INHIBITOR | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885KCNH2 941/4885PDE4A 1129/4885 |
| US-12226418-B2 | Dosing regimen for the treatment of PI3K related disorders | PIK3CA, PIK3CD, PIK3R5 | PIK3CD 2/4885KCNH2 3472/4885PDE4A 581/4885 |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885KCNH2 3201/4885PDE4A 806/4885 |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885KCNH2 3201/4885PDE4A 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.